At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 227 enrolled
Drug / intervention
Reslizumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Efficacy and Safety Study of Reslizumab (CTx55700) in the Treatment of Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years
In Brief
A Phase 3 clinical trial evaluating Reslizumab and Saline for Eosinophilic Esophagitis. Completed, enrolled 227 participants across 37 sites in 2 countries.
Detailed Summary
This trial will study three doses of reslizumab versus placebo in children with eosinophilic esophagitis (EE). The objectives of the trial will be to study the effectiveness of reslizumab in improving the clinical signs and symptoms and reducing esophageal eosinophils as well as assessing the safety profile compared to placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEosinophilic Esophagitis
CountriesCanada, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 2007
Enrollment StartMar 2008
Primary CompletionOct 2009
TodayJul 2026
First PostedOct 2, 2007
Enrollment StartMar 1, 2008
Primary CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 18.8 years ago
Interventions
Reslizumabbiological
Salineother